OSTEOARTHRITIS TREATMENT COMPOSITION USING iPSC-DERIVED MITOCHONDRIA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoarthritis, such as nonsteroidal anti-inflammatory drugs, are associated with gastrointestinal side effects, and there is a need for more effective and safer therapeutic options that can also promote cartilage regeneration.
Innovation Solution
A pharmaceutical composition using induced pluripotent stem cell (iPSC)-derived mitochondria as an active ingredient, which increases mitochondrial activity, suppresses cartilage degradation factors, and promotes cartilage regeneration by overexpressing uncoupling protein 2 (UCP2).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If nonsteroidal anti-inflammatory drugs are used to treat osteoarthritis, then pain and inflammation are reduced, but gastrointestinal side effects occur
Solution Approach 1:
The patent uses mitochondria as an intermediary carrier to deliver therapeutic agents directly to chondrocytes in the joint cavity. The mitochondria serve as a natural vehicle that transports drugs or genetic material to the target cells, bypassing the gastrointestinal tract and eliminating associated side effects while maintaining therapeutic efficacy for pain and inflammation reduction
Solution Approach 2:
The patent replaces the conventional systemic drug administration route (oral ingestion through gastrointestinal tract) with a localized biological delivery system using mitochondria. This substitution eliminates the mechanical interaction with the gastrointestinal system entirely, avoiding ulcers and other GI side effects while achieving targeted therapeutic delivery to osteoarthritis-affected chondrocytes
2Object-affected harmful factors
If conventional drugs are used to treat osteoarthritis, then symptoms are managed, but cartilage regeneration is not promoted
Solution Approach 1:
The patent employs mitochondria with multi-functional capabilities: they simultaneously serve as (1) a delivery vehicle for therapeutic agents, (2) a source of energy (ATP) to support chondrocyte function, and (3) a carrier for genetic material that can stimulate cartilage matrix production. This multi-functionality allows a single intervention to address both symptom management and cartilage regeneration
Solution Approach 2:
The patent alters the functional parameters of chondrocytes by introducing mitochondria that can modify cellular metabolism, enhance energy production, and stimulate anabolic activities. These parameter changes in chondrocyte function lead to increased cartilage matrix synthesis and regeneration, transforming the cells from a degenerating state to a regenerative state
Data Source
AI summary
Provided is a composition for the treatment of osteoarthritis using iPSC-derived mitochondria. Therefore, it was confirmed that the iPSC-derived mitochondria of the present disclosure increased the transplant ability into chondrocytes, suppressed the expression of the MMP series, which were cartilage metabolic factors, and suppressed the death of chondrocytes. In addition, it was confirmed that the iPSC-derived mitochondria suppressed damage to joint tissue in an osteoarthritis animal model, reduced immune cells, and increased immune osteoarthritis-causing regulatory cells. In addition, it was confirmed that the expression of UCP2 in iPSC-derived mitochondria was significantly increased compared to mitochondria isolated from other origin cells, and that UCP2 was closely related to the treatment effect of osteoarthritis caused by mitochondrial transplantation. In addition, it was confirmed that iPSC-derived mitochondria overexpressing UCP2 improves osteoarthritis as a cartilage regeneration effect.